Long non-coding RNA ANRIL is associated with a poor prognosis of osteosarcoma and promotes tumorigenesis via PI3K/Akt pathway
Conclusions Upregulated expression of ANRIL is associated with the tumor development and prognosis of OS. ANRIL may regulate the function of OS cells through the AKT pathway. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - February 14, 2018 Category: Cancer & Oncology Source Type: research
Healthcare-resource utilization associated with radiation to bone across eight European countries: results from a retrospective study
Conclusion HRU increased following radiation to bone across all countries studied. Agents that prevent severe pain and delay the need for radiation have the potential to reduce the burden imposed on healthcare resources and patients. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - February 6, 2018 Category: Cancer & Oncology Source Type: research
Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: a systematic review of the real world data
Conclusions BM and SREs are common problems in non-trial breast cancer populations. Patient demographics, clinical stage, tumor pathological type, molecular receptors status are significantly risk factors for incidence of BM, SREs and the survival. The unique characteristics of BM and SREs in breast cancer patients should be taken into account in future randomized controlled trials, as to optimize individual treatment options and assure a maximally long good quality of life. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - February 4, 2018 Category: Cancer & Oncology Source Type: research
Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer
This study was to analyze the correlation between MDSC subsets and CCL2 level in lung cancer model. G-MDSC and M-MDSC from the blood and parenchyma were analyzed by flow cytometry and western blot in the lung tumor model. CCL2 was detected by ELISA assay, real-time PCR, western blot and flow cytometry. Furthermore, the therapeutic effects of combination treatment combining CCL2 antagonist and anti-PD1 antibody were assessed. Results showed that MDSC subsets had a positive correlation with CCL2, suggesting CCL2 may attract MDSC into the parenchyma. Gene and protein expression of CCL2, as well as the CCL2 surface expression ...
Source: Journal of Bone Oncology - January 31, 2018 Category: Cancer & Oncology Source Type: research
Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in osteosarcoma cancer
This study was to analyze the correlation between MDSC subsets and CCL2 level in osteosarcoma cancer model. G-MDSC and M-MDSC from the blood and parenchyma were analyzed by flow cytometry and western blot in the osteosarcoma tumor model. CCL2 was detected by ELISA assay, real-time PCR, western blot and flow cytometry. Furthermore, the therapeutic effects of combination treatment combining CCL2 antagonist and anti-PD1 antibody were assessed. Results showed that MDSC subsets had a positive correlation with CCL2, suggesting CCL2 may attract MDSC into the parenchyma. Gene and protein expression of CCL2, as well as the CCL2 sur...
Source: Journal of Bone Oncology - January 8, 2018 Category: Cancer & Oncology Source Type: research
